Stockreport

Arrowhead outlines REDEMPLO expansion with $60,000 annual price and expects top-line SHASTA-3/4 data in Q3 2026 [Seeking Alpha]

Novartis AG  (NVS) 
Last novartis ag earnings: 4/28 01:00 am Check Earnings Report
US:NYSE Investor Relations: novartis.com/investors
PDF Dr. Christopher Anzalone, CEO, announced Arrowhead's first FDA approval for REDEMPLO, marking a major milestone as the company transitions to a commercial-stage entity. [Read more]